Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches
Recruiting · NCT06856850 · Observational (researchers observe without assigning treatment) · Lead sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
View the official record on ClinicalTrials.gov →What this trial is about
Diagnosis of ALS/FTD disease spectrum is challenging because it largely relies on clinical symptoms. Identifying novel biomarkers is essential for a paradigm shift towards a more precise biological-based diagnosis. To achieve this aim, having access to proper specimens and analytical methods is crucial. Our team of experts in neurology, biology, chemistry, physics, and AI will explore ALS/FTD from novel perspectives using transcriptomics, proteomics, genomics and other innovative approaches to analyzing easily accessible tissues. The seed amplification assay (SAA) will be also exploited to detect pathological TDP-43. This project aims to create disease fingerprints useful for patient stratification and monitoring of disease progression, and to evaluate the therapeutic efficacy in clinical trials, thus overcoming the limits of clinical interpretation. Discovering new biomarkers and cellular pathways will improve the diagnosis and treatment of these devastating diseases.
Who can take part
Inclusion criteria
- Clinical criteria for ALS (Brooks et al., 2000; de Carvalho M., 2008), FTD (GornoTempini et al., 2011; Rascovsky et al., 2011)
Where it is running
4 locations listed.
- Fondazione IRCCS Istituto Neurologico Carlo Besta - Milan, Italy
- Università degli Studi di Napoli "Federico II" - Naples, Italy
- Azienda Ospedaliero Universitaria di Sassari - Sassari, Italy
- Consorzio Interuniversitario Risonanze Magnetiche Metallo Proteine (CIRMMP) - Sesto Fiorentino, Italy